Compare Moderna, Inc. (MRNA) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Nasdaq Inc — how do they compare? Moderna, Inc. trades at $63.68 (market cap $24.18B), while Nasdaq Inc trades at $95.84 (market cap $53.11B). The key difference: Nasdaq Inc is far larger — about 2.2× Moderna, Inc.'s market cap, and Nasdaq Inc pays a 1.22% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | NDAQ | |
|---|---|---|
Market Cap | $24.18B | $53.11B |
Sector | Health | Financials |
52-Week High | $81.80 | $100.98 |
52-Week Low | $22.36 | $76.85 |
Enterprise Value | $20.33B | $59.57B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Nasdaq (NDAQ) trades at $95.92, up 0.31% on the day, with a bullish technical signal from moving averages and strong support at $95. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.07 exceeding expectations, and revenue growth accelerated to $8.26 billion in 2025. Recent news includes the acquisition of LeveL Markets, advancing its always-on markets strategy.
The outlook is positive, supported by analyst consensus of $109.20 price target and 61% buy ratings. Key opportunities include sustained revenue growth and strategic acquisitions, while risks involve competitive pressures and market volatility. The stock offers a dividend yield with recent payouts of $0.31 per share.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
